Issue: Equal Access to Care

Equal access to drugs that treat both a brain tumour and associated conditions, as well as the related financial burden, is an important issue for brain tumour patients and their families across Canada. Where a patient lives should never determine the treatment for a brain tumour.

The diagnosis of a brain tumour can be overwhelming and confusion about access to drugs is an unnecessary burden. Quite simply, it is confusing for patients and families to see provincial health care plans making different decisions based on the same evidence. We advocate for better access to all brain tumour drugs and increased transparency and collaboration among all stakeholders with the aim to help every Canadian affected by a brain tumour.

And so, any time there is an opportunity for patients to have their voices heard about access to medication is important and Brain Tumour Foundation of Canada supports patient advocacy on this issue.

June 2019: Brain Tumour Foundation of Canada is pleased to see universal access to essential medicines as a cornerstone of the Advisory Council’s recommendations for national Pharmacare

We look forward to working with federal and provincial government partners to ensure oral cancer drugs and other essential therapies for brain tumours are included in this discussion.
Read the full report from Health Canada.
Access to Standard Treatment for Malignant Brain Tumours is not Universal in Canada. 

Find out whether Temozolomide is funded by your province, with our new map.
March 2018: Read more about how this issue affects brain tumour patients on our blog.
CanCertainty for all Canadians'CanCertainty is needed for all Canadians'.  Brain Tumour Foundation of Canada has joined with more than 20 other cancer groups to demand 'CanCertainty' for all cancer patients when it comes to their chemotherapy. 60 per cent of all new cancer treatments being developed are oral medications - including Temozolomide for brain tumours. And Temozolomide is the standard of care chemotherapy for brain tumour patients. Yet, in several provinces this, and many other provincially approved oral treatments for cancer patients are not covered.

The treatment of a brain tumour can vary widely depending on its type and location, the age of a patient and many other individual elements. But treatment should be defined by an individual's medical needs and should never be determined by cost or where a patient lives. Find out more about this issue at CanCertainty.ca and lend your voice to the call for fairness.

Ways We Are Addressing this Issue

Equal access to treatments and drugs and the associated financial burden is an important issue for brain tumour patients and their families in Canada. Brain Tumour Foundation of Canada is active on this complex issue in the following ways:

  • Working on equal access to Temozolomide (Temodal) for all patients in Canada. We are working with other cancer organizations about the disparity in coverage for oral chemotherapies through the CanCertainty campaign. Brain Tumour Foundation of Canada has taken part in meetings with government officials on this issue, ensuring that the voice and stories of brain tumour patients are being heard.
     
  • Monitoring the drug approval process and communicating next steps and opportunities for action to the brain tumour community. This includes watching for any new approval processes for drugs like Avastin and providing patient input when possible - through approval bodies like pCODR.
     
  • Working with the Canadian Cancer Action Network who advocate for the entire cancer community to by working with federal and provincial decision makers to ensure a pan-Canadian system evolves that optimizes care and treatment outcomes through all phases of the cancer continuum. In 2011, Brain Tumour Foundation of Canada signed the organization's Statement of Principles titled, Sharing Responsibility for Cancer Drug Costs (opens a PDF).
     
  • Providing information for you to advocate for your best care, including gaining access to services and treatments

 

Watch this space for future opportunties to lend your voice to this important issue.

< Back to Advocacy Issues

 

 

 

Share This

Featured Story

Janet and Adam's Story: Beating the odds to share another birthday together

Turning the same age, on the same day as my husband, never gets old. They call us, Astro-Twins. According to many different sources, the odds were low that it would have lasted. His Auntie May discouraged it from the start saying, “You are both Sagittarians and should NOT be together.” My daughter Isobel did a quick calculation. Fun fact. In a group of 100 people there is a 2.8% chance of two people having the same birthday.

Learn more

Spotlight

Lawrence's Story: Be happy, live happy

Lawrence, a successful businessman, is not one to take a decline in memory lightly. Lawrence was in Winnipeg, at home on leave from his...

Learn more

Alicia's Story: You gotta laugh every day

It’s hard to capture an infectious giggle in words, but that’s exactly what you get when you speak to Alicia. Alicia is now 20 years...

Learn more

Upcoming Events

  • 16/Dec/2019: Virtual Support Group for Caregivers (Eastern Canada): Virtual Support Group for Caregivers (Eastern Canada)... Learn more >
  • 16/Dec/2019: Guelph Support Group: Meets at Hospice Wellington, Community Program Room, 795 Scottsdale Avenue,... Learn more >
  • 17/Dec/2019: New Glasgow Support Group: Meets at East Haven Manor, 695 East River Road in New Glasgow, NS ... Learn more >
  • 18/Dec/2019: Ottawa Support Group: Meets at the Maplesoft Centre at 1500 Alta Vista Drive, Ottawa, ON.... Learn more >
View All Events >
Thank you to the donors whose contributions make this website and all programs, services and research possible.

Copyright © 2019 Brain Tumour Foundation of Canada. Charitable Registration #BN118816339RR0001